Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice

Table 4

Treatments for glioblastoma administered to 60 patients who received bevacizumab therapy.

Bevacizumab treatment sub-groups (number of subjects)	Period when treatment for glioblastoma was received	Treatment received for glioblastoma
		Surgical resection	Any radiotherapy	Temozolomide	Bevacizumab	Other chemotherapy
		n (%)	n (%)	n (%)	n (%)	n (%)
Bevacizumab received before tumor recurrence (n = 10)	At diagnosis	9 (90.0)	10 (100.0)	10 (100.0)	10 (100.0)	2 (20.0)
	At first recurrence	2 (20.0)	0 (0.0)	0 (0.0)	2 (20.0)	3 (30.0)
Bevacizumab received at first tumor recurrence (n = 43)	At diagnosis	29 (67.4)	43 (100.0)	43 (100.0)	0 (0.0)	0 (0.0)
	At first recurrence	0 (0.0)	2 (4.7)	9 (20.9)	43 (100.0)	19 (44.2)
Bevacizumab received at second tumor recurrence (n = 7)	At diagnosis	7 (100.0)	6 (85.7)	5 (71.4)	0 (0.0)	2 (28.6)
	At first recurrence	7 (100.0)	3 (42.9)	6 (85.7)	0 (0.0)	1 (14.3)
	At second recurrence	0 (0.0)	1 (14.3)	0 (0.0)	7 (100.0)	5 (71.4)